Detection of Intraamniotic Infection
AssigneeHologic, Inc.
InventorThomas H. Grove
Life of this patent
Estimating the term…
Abstract
The present invention concerns the identification of biomarkers and groups or combinations of biomarkers that can be used for non-invasive diagnosis of intra-amniotic infection, and diagnostic assays using such biomarkers.
Claims24
1-33. (canceled)
A method for the diagnosis of intra-amniotic infection in a pregnant female mammalian subject comprising:
- (a) measuring in a sample of cervical-vaginal fluid obtained from said subject the levels of interleukin-6 (IL-6) and fetal fibronectin (fFN) relative to the corresponding levels of said proteins in normal cervical-vaginal fluid or cervical-vaginal fluid known to be indicative of intra-amniotic infection;
- and
- (b) diagnosing said subject with intra-amniotic infection if each of said levels of each of said proteins in said sample is determined to show a statistically significant difference relative to the corresponding levels of each of said proteins in said normal cervical-vaginal fluid, or is determined not to show a statistically significant difference relative to the corresponding levels of each of said proteins in said cervical-vaginal fluid known to be indicative of intra-amniotic infection.
The method of claim 34 or 52 wherein said protein level is determined by methods comprising the use of an immunoassay, a protein array, an immunochromatographic test, mass spectrometry, or combinations thereof.
A method for determining signs and symptoms indicating intra-amniotic infection comprising
- (a) measuring in a sample of cervical-vaginal fluid obtained from said subject the levels of interleukin-6 (IL-6) and fetal fibronectin (fFN), relative to the levels of IL-6 and fFN in normal cervical-vaginal fluid or cervical-vaginal fluid known to be indicative of intra-amniotic infection;
- and
- (b) diagnosing said subject with intra-amniotic infection if each of said levels of IL-6 and fFN in said sample are determined to show a statistically significant difference relative to the corresponding levels of IL-6 and fFN in said normal cervical-vaginal fluid, or are determined not to show a statistically significant difference relative to the corresponding levels of IL-6 and fFN in said cervical-vaginal fluid known to be indicative of intra-amniotic infection.
An immunochromatographic test device comprising one or more chromatography strips for the detection of interleukin-6 (IL-6) and fetal fibronectin (fFN).
Dependencies are inferred from the claim text.